On the stock market since 2015, it operates in the world of health and science. It has 1,605 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 5% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 90% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $655.4M a year; the problem isn’t sales — it’s costs running above that number.
There is $457.5M in the vault; even if every debt were paid off, $167.5M would remain.
Over the last 12 months, company executives reported 46 buys and 33 sells. Management buying with its own money is usually read as a good sign.
A loss of $136.2M against $655.4M in annual sales.
On our five-subject report card, NVCR sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NVCR has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.